Evaluation of Very little Residual Disease in Standard-Risk AML
Despite the molecular heterogeneity of standard-risk intense myeloid leukemia (AML), treatment choices are based upon a restricted number of molecular genetic markers and morphology-based assessment … position of the National Health Service (NHS) or the …
See Initial Article